NICE Gives Celgene’s Revlimid Benefit Of the Doubt For MDS
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite reservations about a complex patient access scheme – and its financial benefit to the publicly funded National Health Service – Britain’s NICE has given the nod to Celgene’s Revlimid for MDS.